Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*

LOS ANGELES--(BUSINESS WIRE)--Jan 15, 2026--

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it has partnered with Truemed to provide qualified customers the option to purchase Tru Niagen ®, the number one NAD+ supplement in the United States*, using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds on its direct-to-consumer website, www.truniagen.com. Qualified customers may use HSA/FSA funds to purchase Tru Niagen with a Truemed Letter of Medical Necessity (LMN) issued by a licensed provider.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115568615/en/

The update expands payment flexibility for consumers seeking science-backed nutritional support for cellular health, allowing eligible customers to use pre-tax health dollars to purchase Tru Niagen through a streamlined checkout experience powered by Truemed.

“Tru Niagen is the category-defining NAD+ supplement, backed by deep scientific investment and rigorous quality standards,” said Rob Fried, CEO of Niagen Bioscience. “By enabling the spending of HSA and FSA funds on Tru Niagen, we are making Tru Niagen more accessible.”

Tru Niagen features Niagen ® (patented nicotinamide riboside, or NR), the most efficient and high-quality NAD+ booster available. A coenzyme vital to cellular health, NAD+ plays a critical role in cellular energy production and DNA repair. Niagen is backed by rigorous quality and scientific standards, supported by more than 40 peer-reviewed human clinical studies, over 500 published scientific papers, and more than 50 patents worldwide, and is recognized by some of the world’s most stringent regulatory bodies.

“Truemed exists to make preventive health tools more financially accessible,” said Justin Mares, Co-Founder and CEO of Truemed. “We are excited to help qualified customers use HSA/FSA funds to support their healthspan with Tru Niagen.”

The process is simple

For one-time purchases (pay with HSA/FSA at checkout)

For subscriptions (get reimbursed after purchase):

To learn more and shop Tru Niagen with HSA/FSA funds, visit www.truniagen.com and look for “Shop with HSA/FSA” at checkout. Truemed is for qualified customers. HSA/FSA tax savings vary. Learn more at truemed.com/disclosures.

For additional information on the research behind Niagen, visit www.niagenbioscience.com.

About Niagen Bioscience:

Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.

At the heart of its clinically proven product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen ®, the number one NAD+ boosting oral supplement in the United States* (available at www.truniagen.com ), and Niagen Plus ™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( www.niagenplus.com ). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.

* Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024).

Forward Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could,” “predicts,” “projects,” “continue,” “would” or the negative of such terms or other similar expressions.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those described. These risks and uncertainties include, but are not limited to, inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; including unanticipated developments in and risks related to the Company’s ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company’s ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company’s ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company’s ability to maintain and enforce the Company’s existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities, including with respect to products seeking to compete in our market; economic and market instability, including as a result of tariffs or trade conflicts; and the risks and uncertainties associated with our business and financial condition in general, described in our filings with the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q as filed with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Qualified Customers may now purchase Tru Niagen at www.truniagen.com using HSA/FSA funds with a Truemed Letter of Medical Necessity (LMN)

CARACAS, Venezuela (AP) — President Donald Trump is set to meet Thursday at the White House with Venezuelan opposition leader María Corina Machado, whose political party is widely considered to have won 2024 elections rejected by then-President Nicolás Maduro before the United States captured him in an audacious military raid this month.

Less than two weeks after U.S. forces seized Maduro and his wife at a heavily guarded compound in Caracas and brought them to New York to stand trial on drug trafficking charges, Trump will host the Nobel Peace Prize laureate Machado, having already dismissed her credibility to run Venezuela and raised doubts about his stated commitment to backing democratic rule in the country.

“She’s a very nice woman,” Trump told Reuters in an interview about Machado. “I’ve seen her on television. I think we’re just going to talk basics.”

The meeting comes as Trump and his top advisers have signaled their willingness to work with acting President Delcy Rodríguez, who was Maduro’s vice president and along with others in the deposed leader's inner circle remain in charge of day-to-day governmental operations.

Rodríguez herself has adopted a less strident position toward Trump and his “America First” policies toward the Western Hemisphere, saying she plans to continue releasing prisoners detained under Maduro — a move reportedly made at the behest of the Trump administration. Venezuela released several Americans this week.

Trump, a Republican, said Wednesday that he had a “great conversation” with Rodríguez, their first since Maduro was ousted.

“We had a call, a long call. We discussed a lot of things,” Trump told reporters. “And I think we’re getting along very well with Venezuela.”

In endorsing Rodríguez, Trump has sidelined Machado, who has long been a face of resistance in Venezuela. She had sought to cultivate relationships with Trump and key advisers like Secretary of State Marco Rubio among the American right wing in a political gamble to ally herself with the U.S. government. She also intends to have a meeting in the Senate on Thursday afternoon.

Despite her alliance with Republicans, Trump was quick to snub her following Maduro’s capture. Just hours afterward, Trump said of Machado that “it would be very tough for her to be the leader. She doesn’t have the support within or the respect within the country. She’s a very nice woman, but she doesn’t have the respect.”

Machado has steered a careful course to avoid offending Trump, notably after winning last year’s Nobel Peace Prize, which Trump coveted. She has since thanked Trump and offered to share the prize with him, a move that has been rejected by the Nobel Institute.

Machado’s whereabouts have been largely unknown since she went into hiding early last year after being briefly detained in Caracas. She briefly reappeared in Oslo, Norway, in December after her daughter received the Nobel Peace Prize on her behalf.

The industrial engineer and daughter of a steel magnate began challenging the ruling party in 2004, when the nongovernmental organization she co-founded, Súmate, promoted a referendum to recall then-President Hugo Chávez. The initiative failed, and Machado and other Súmate executives were charged with conspiracy.

A year later, she drew the anger of Chávez and his allies again for traveling to Washington to meet President George W. Bush. A photo showing her shaking hands with Bush in the Oval Office lives in the collective memory. Chávez considered Bush an adversary.

Almost two decades later, she marshaled millions of Venezuelans to reject Chávez’s successor, Maduro, for another term in the 2024 election. But ruling party-loyal electoral authorities declared him the winner despite ample credible evidence to the contrary. Ensuing anti-government protests ended in a brutal crackdown by state security forces.

Janetsky reported from Mexico City. AP Diplomatic Writer Matthew Lee in Washington contributed to this report.

FILE - Opposition leader Maria Corina Machado gestures to supporters during a protest against President Nicolas Maduro the day before his inauguration for a third term, in Caracas, Venezuela, Thursday, Jan. 9, 2025. (AP Photo/Ariana Cubillos, file)